Translate Bio to Present at Upcoming Investor Conferences
February 19, 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Executive Leadership Appointments
December 12, 2019 16:15 ET
|
Translate Bio, Inc.
-- Appointment of Frank DeRosa, Ph.D. to Chief Technology Officer, and transition of Michael Heartlein, Ph.D. to Executive Vice President and Founder -- -- Appointment of Paul Burgess to Chief...
Translate Bio to Present at Upcoming Investor Conferences
November 13, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Third Quarter 2019 Financial Results and Reviews Recent Highlights
November 06, 2019 16:11 ET
|
Translate Bio, Inc.
-- Advanced CF program with single-ascending dose (SAD) clinical data presentation and continued enrollment and dosing in multiple-ascending dose (MAD) portion of Phase 1/2 trial -- -- Prioritized...
Translate Bio Presents MRT5005 Data at the 33rd Annual North American Cystic Fibrosis Conference
October 31, 2019 12:15 ET
|
Translate Bio, Inc.
NASHVILLE, Tenn., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Upcoming MRT5005 Presentations at the 33rd Annual North American Cystic Fibrosis Conference
October 01, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 3rd Annual Chardan Genetic Medicines Conference
September 30, 2019 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Proposed Public Offering of Common Stock
September 17, 2019 16:01 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
Translate Bio Announces Strategic Manufacturing Agreement with AMRI in Support of Messenger RNA (mRNA) Manufacturing
September 12, 2019 16:05 ET
|
Translate Bio, Inc.
-- Agreement provides Translate Bio with customized and dedicated manufacturing space for cGMP mRNA production for current and future programs -- LEXINGTON, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE)...
Translate Bio Announces Pipeline Program Update
September 09, 2019 16:05 ET
|
Translate Bio, Inc.
- Prioritizing and expanding pulmonary disease programs based on early positive cystic fibrosis (CF) data for MRT5005, the first inhaled mRNA therapeutic – - Discontinuing development of MRT5201, a...